Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women.

New pre-exposure prophylaxis (PrEP) strategies tailored to the needs and expectations of individuals at risk of HIV acquisition are needed. In the CAPRISA 082 prospective cohort study in KwaZulu-Natal, South Africa, sexually active women aged 18 to 30 reported, through interviewer-administered quest...

Descripción completa

Detalles Bibliográficos
Publicado en:AIDS & Behavior Vol. 27; no. 11; pp. 3596 - 3603
Autores principales: Jansen van Vuuren, Claudia J., Lewis, Lara, Harkoo, Ishana, Dawood, Halima, Mansoor, Leila E.
Formato: research tables/charts Journal Article
Publicado: Springer Nature Nov2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=173150935&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 173150935
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10907165
        G1T
      jtl: AIDS & Behavior
      issn: 10907165
      maglogo: N
    pubinfo:
      dt: Nov2023
      vid: 27
      iid: 11
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        173150935
        163865096
        173150935
        173150935
        10.1007/s10461-023-04072-6
        173150935
      ppf: 3596
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women.
      aug:
        au:
          Jansen van Vuuren, Claudia J.
          Lewis, Lara
          Harkoo, Ishana
          Dawood, Halima
          Mansoor, Leila E.
        affil: Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
      sug:
        subj:
          Contraceptive Agents Therapeutic Use
          Contraceptive Agents Administration and Dosage
          Dosage Forms
          Pre-Exposure Prophylaxis
          Women
          HIV Infections Prevention and Control
          Life Experiences
          Human
          Female
          Adolescence
          Adult
          Treatment Outcomes
          Prospective Studies
          South Africa
          Interviews
          Questionnaires
          Administration, Oral
          Injections
          Intrauterine Devices
          Univariate Statistics
          Multivariate Analysis
          Regression
          Medroxyprogesterone Acetate
          Confidence Intervals
          Odds Ratio
          Sexual Health
          Reproductive Health
          Descriptive Statistics
          Funding Source
          Adolescent: 13-18 years
          Adult: 19-44 years
          Female
      ab: New pre-exposure prophylaxis (PrEP) strategies tailored to the needs and expectations of individuals at risk of HIV acquisition are needed. In the CAPRISA 082 prospective cohort study in KwaZulu-Natal, South Africa, sexually active women aged 18 to 30 reported, through interviewer-administered questionnaires, on their prior contraceptive experience and interest in both approved and potential future PrEP dosage forms (oral PrEP, long-acting injectable PrEP, and PrEP implants) between March 2016 and February 2018. Univariable and multivariable Poisson regression models with robust standard errors were used to detect associations between women's prior and current contraceptive use and interest in PrEP options. Of 425 women enrolled, 381 (89.6%) had used at least one modern female contraceptive method previously, with injectable depot medroxyprogesterone acetate (DMPA) being used by 79.8% (n = 339). Women were more likely to show interest in a future PrEP implant if they were currently using (aRR 2.1, CI 1.43–3.07, p = 0.0001) or had ever used (aRR 1.65, CI 1.14–2.40, p = 0.0087) a contraceptive implant, and were more likely to choose an implant as their first choice method than the implant-naïve (current users aRR 3.2, CI 1.79–5.73, p < 0.0001; "ever" users aRR 2.12, CI 1.16–3.86, p = 0.0142). Women were more interested in injectable PrEP if they had used injectable contraceptives (current users aRR 1.24, CI 1.06–1.46, p = 0.0088; "ever" users aRR 1.72, CI 1.20–2.48, p = 0.0033); and were more interested in oral PrEP if they had ever used oral contraceptives (aRR 1.3, CI 1.06–1.59, p = 0.0114). This apparent relationship between women's contraceptive experience and their interest in novel forms of PrEP in an equivalent dosage form may play a future role in strengthening HIV prevention efforts in women at high risk of HIV acquisition.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N